Dana-Farber Cancer Institute
Newton, MA, United States
Dr. Sharon is the Clinical and Translational Director of the Immunotherapy Toxicity Program at Dana-Farber Cancer Institute and an Associate Professor of Medicine at Harvard Medical School, roles he began in August 2023. Prior to his current positions, Dr. Sharon held pivotal roles at the National Cancer Institute’s (NCI) Cancer Therapy Evaluation Program (CTEP) and served as an attending physician in the NCI’s Developmental Therapeutics Clinic (DTC). During his time at the NCI, he helped co-direct the immunotherapy drug development portfolio for CTEP, overseeing clinical trials for which the NCI served as the sponsor in collaboration with industry and academic colleagues. CTEP is the largest government sponsor of clinical trials globally, enrolling around 20,000 patients on NCI-sponsored clinical trials, with trial sites throughout the United States and around the globe. His tenure at the NCI coincided with an explosion of interest in immunotherapy, and Dr. Sharon’s role involved complementing industry efforts with public health-oriented drug development, bringing novel clinical trials to both the academic and community oncology settings. Dr. Sharon helped shape innovative, practice-changing clinical trials, resulting in numerous FDA approvals for both rare and common tumors with a variety of agents under his purview. Dr. Sharon's focus on biomarker-driven, translationally-rich clinical trials is intended to leverage research into both efficacy and adverse events.
Monday, October 27, 2025
4:30 PM – 5:00 PM Central Time
Disclosure(s): D. E. Shaw Research: Consultant (Terminated, January 11, 2024); Mallincrkrodt Pharmaceuticals: Advisor or Review Panel Member (Terminated, November 28, 2024)
